

ASTRO MED INC /NEW/  
Form 10-Q  
September 07, 2007  
Table of Contents

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 10-Q**

---

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended August 4, 2007

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-13200

---

**Astro-Med, Inc.**

(Exact name of registrant as specified in its charter)

---

Rhode Island  
(State or other jurisdiction of  
incorporation or organization)

05-0318215  
(I.R.S. Employer

Identification No.)

600 East Greenwich Avenue, West Warwick, Rhode Island

02893

Edgar Filing: ASTRO MED INC /NEW/ - Form 10-Q

(Address of principal executive offices)

(401) 828-4000

(Zip Code)

(Registrant's telephone number, including area code)

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes . No .

Indicate by check mark whether the registrant is a large accelerated filer or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act.

Large accelerated filer . Accelerated filer . Non-accelerated filer .

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes . No .

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Common Stock, \$.05 Par Value 6,910,082 shares

(excluding treasury shares) as of August 29, 2007

---

**Table of Contents**

ASTRO-MED, INC.

INDEX

|   | <b>Page No.</b> |
|---|-----------------|
| <b><u>Part I. Financial Information</u></b>   |                 |
| Item 1. Financial Statements (Unaudited)  |                 |
| <u>Condensed Consolidated Balance Sheets August 4, 2007 and January 31, 2007</u>  | 3               |
| <u>Condensed Consolidated Statements of Operations-Three-Months and Six Months Ended August 4, 2007 and July 29, 2006</u> | 4               |
| <u>Condensed Consolidated Statements of Cash Flows-Six-Months Ended August 4, 2007 and July 29, 2006</u>                  | 5               |
| <u>Notes to Unaudited Condensed Consolidated Financial Statements August 4, 2007</u>                                      | 6-10            |
| <u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>                      | 11-15           |
| <u>Item 3. Quantitative and Qualitative Disclosures about Market Risk</u>   | 16              |
| <u>Item 4. Controls and Procedures</u>  | 16              |
| <b><u>Part II. Other information</u></b>  | 16              |
| <b><u>Item 1. Legal Proceedings</u></b>   | 16              |
| <b><u>Item 1A. Risk Factors</u></b>   | 16              |
| <b><u>Item 2. Unregistered Sale of Securities and Use of Proceeds</u></b>   | 17              |
| <b><u>Item 4. Submission of Matters to a Vote of Stockholders</u></b>   | 17              |
| <b><u>Item 6. Exhibits</u></b>  | 18              |
| <b><u>Signatures</u></b>  | 18              |
| Management Certifications   |                 |

**Table of Contents****Part I. FINANCIAL INFORMATION****ASTRO-MED, INC.****CONDENSED CONSOLIDATED BALANCE SHEETS**

|  | <b>August 4,<br/>2007<br/>(Unaudited)</b> | <b>January 31, 2007</b> |
|--|---|-------------------------|
| <b>ASSETS</b>  |   |                         |
| <b>CURRENT ASSETS</b>  |   |                         |
| Cash and Cash Equivalents  | \$ 3,824,049                              | \$ 4,595,570            |
| Securities Available for Sale  | 12,080,678                                | 12,334,065              |
| Accounts Receivable, Net   | 12,832,157                                | 12,112,676              |
| Inventories  | 12,495,496                                | 11,394,763              |
| Prepaid Expenses and Other Current Assets  | 718,750                                   | 841,528                 |
| Deferred Tax Assets  | 2,757,672                                 | 2,889,438               |
| <b>Total Current Assets</b>  | <b>44,708,802</b>                         | <b>44,168,040</b>       |
| <b>PROPERTY, PLANT AND EQUIPMENT</b>   | <b>32,679,104</b>                         | <b>29,313,917</b>       |
| Less Accumulated Depreciation  | (21,855,918)                              | (21,349,666)            |
| <b>Total Property, Plant and Equipment, Net</b>  | <b>10,823,186</b>                         | <b>7,964,251</b>        |
| <b>OTHER ASSETS</b>  |   |                         |
| Goodwill   | 2,336,721                                 | 2,336,721               |
| Long Term Investments  |   | 3,200,000               |
| Amounts Due from Officers  |   | 27,050                  |
| Other  | 239,806                                   | 304,918                 |
|  | <b>\$ 58,108,515</b>                      | <b>\$ 58,000,980</b>    |
| <b>LIABILITIES AND SHAREHOLDERS EQUITY</b>   |   |                         |
| <b>CURRENT LIABILITIES</b>   |   |                         |
| Accounts Payable   | \$ 2,936,587                              | \$ 3,559,518            |
| Accrued Compensation   | 1,825,877                                 | 2,475,219               |
| Accrued Expenses   | 1,710,239                                 | 2,626,019               |
| Deferred Revenue   | 621,033                                   | 805,352                 |
| Income Taxes Payable   | 452,547                                   | 408,114                 |
| <b>Total Current Liabilities</b>   | <b>7,546,283</b>                          | <b>9,874,222</b>        |
| Other Liabilities  | 1,552,111                                 |                         |
| Deferred Tax Liabilities   | 2,232,701                                 | 2,168,416               |
| <b>TOTAL LIABILITIES</b>   | <b>11,331,095</b>                         | <b>12,042,638</b>       |
| <b>SHAREHOLDERS EQUITY</b>   |   |                         |
| Common Stock, \$.05 Par Value, Authorized 13,000,000 Shares; Issued, 8,034,188 and 7,905,319<br>Shares, respectively | 401,714                                   | 395,270                 |
| Additional Paid-In Capital   | 31,740,688                                | 30,638,755              |
| Retained Earnings  | 21,853,767                                | 22,282,495              |
| Treasury Stock, at Cost, 1,124,106 Shares  | (7,644,647)                               | (7,644,647)             |
| Accumulated Other Comprehensive Income, Net of Taxes   | 425,898                                   | 286,469                 |

Edgar Filing: ASTRO MED INC /NEW/ - Form 10-Q

|                           |               |               |
|---------------------------|---------------|---------------|
| TOTAL SHAREHOLDERS EQUITY | 46,777,420    | 45,958,342    |
|                           | \$ 58,108,515 | \$ 58,000,980 |

See Notes to Consolidated Financial Statements

-3-

**Table of Contents****ASTRO-MED, INC.****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

|  | <b>Three-Months Ended</b> |                 | <b>Six-Months Ended</b> |                 |
|--|---------------------------|-----------------|-------------------------|-----------------|
|  | <b>(Unaudited)</b>        |                 | <b>(Unaudited)</b>      |                 |
|  | <b>August 4,</b>          | <b>July 29,</b> | <b>August 4,</b>        | <b>July 29,</b> |
|  | <b>2007</b>               | <b>2006</b>     | <b>2007</b>             | <b>2006</b>     |
| Net Sales                                      | \$ 18,694,484             | \$ 16,266,621   | \$ 35,101,374           | \$ 31,908,144   |
| Cost of Sales                                  | 10,863,924                | 9,270,342       | 20,424,510              | 18,636,145      |
| Gross Profit                                   | 7,830,560                 | 6,996,279       | 14,676,864              | 13,271,999      |
| Costs and Expenses:                            |                           |                 |                         |                 |
| Selling, General and Administrative            | 5,433,462                 | 5,034,680       | 10,560,098              | 9,545,501       |
| Research and Development                       | 1,134,848                 | 944,220         | 2,233,105               | 1,996,901       |
| Operating Expenses                             | 6,568,310                 | 5,978,900       | 12,793,203              | 11,542,402      |
| Operating Income                               | 1,262,250                 | 1,017,379       | 1,883,661               | 1,729,597       |
| Other Income (Expense):                        |                           |                 |                         |                 |
| Investment Income                              | 149,814                   | 142,258         | 319,873                 | 273,005         |
| Other, Net                                     | 64,236                    | 48,152          | 142,798                 | 67,152          |
|  | 214,050                   | 190,410         | 462,671                 | 340,157         |
| Income Before Income Taxes                     | 1,476,300                 | 1,207,789       | 2,346,332               | 2,069,754       |
| Income Tax Provision                           | 590,556                   | 467,580         | 938,589                 | 786,506         |
| Net Income                                     | \$ 885,744                | \$ 740,209      | \$ 1,407,743            | \$ 1,283,248    |
| Net Income per Common Share:                   |                           |                 |                         |                 |
| Basic  | \$ 0.13                   | \$ 0.11         | \$ 0.20                 | \$ 0.19         |
| Diluted  | \$ 0.12                   | \$ 0.10         | \$ 0.19                 | \$ 0.17         |
| Weighted Average Number of Shares Outstanding: |                           |                 |                         |                 |
| Basic  | 6,901,265                 | 6,717,790       | 6,866,104               | 6,721,193       |
| Diluted  | 7,577,748                 | 7,380,374       | 7,573,223               | 7,348,919       |
| Dividends Declared Per Common Share            | \$ 0.05                   | \$ 0.05         | \$ 0.10                 | \$ 0.09         |

See Notes to Consolidated Financial Statements

**Table of Contents****ASTRO-MED, INC.****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

|   | <b>Six-Months Ended<br/>July 29,</b> |                     |
|---|--------------------------------------|---------------------|
|   | <b>August 4,<br/>2007</b>            | <b>2006</b>         |
|   | <b>(Unaudited)</b>                   |                     |
| <b>Cash Flows from Operating Activities:</b>  |                                      |                     |
| Net Income  | \$ 1,407,743                         | \$ 1,283,248        |
| <b>Adjustments to Reconcile Net Income to Net Cash (Used in) Provided by Operating Activities:</b>  |                                      |                     |
| Depreciation and Amortization   | 806,101                              | 749,405             |
| Share-Based Compensation  | 271,076                              | 199,454             |
| Deferred Income Taxes   | 303,971                              | 24,731              |
| Excess Tax Benefit from Share-Based Compensation  | (107,920)                            |                     |
| <b>Changes in Assets and Liabilities:</b>   |                                      |                     |
| Accounts Receivable   | (719,481)                            | (194,585)           |
| Inventories   | (893,470)                            | (561,417)           |
| Other   | 185,094                              | 8,758               |
| Income Taxes Payable  | (285,877)                            | (82,036)            |
| Accounts Payable and Accrued Expenses   | (1,637,584)                          | 2,365               |
| Total Adjustments   | (2,078,090)                          | 146,675             |
| <b>Net Cash (Used in) Provided by Operating Activities</b>  | <b>(670,347)</b>                     | <b>1,429,923</b>    |
| <b>Cash Flows from Investing Activities:</b>  |                                      |                     |
| Proceeds from Maturities of Securities Available for Sale   | 2,464,828                            | 2,276,873           |
| Purchases of Securities Available for Sale  | (2,185,000)                          | (4,275,067)         |
| Additions to Property, Plant and Equipment  | (3,729,467)                          | (699,973)           |
| <b>Net Cash (Used in) Investing Activities</b>  | <b>(3,449,639)</b>                   | <b>(2,698,167)</b>  |
| <b>Cash Flows from Financing Activities:</b>  |                                      |                     |
| Proceeds from Common Shares Issued Under Employee Benefit Plans and Exercises of Stock Options  | 729,381                              | 708,664             |
| Purchases of Treasury Stock   |                                      | (564,000)           |
| Excess Tax Benefit from Share-Based Compensation  | 107,920                              |                     |
| Dividends Paid  | (688,836)                            | (605,110)           |
| <b>Net Cash Provided by (Used in) Financing Activities</b>  | <b>148,465</b>                       | <b>(460,446)</b>    |
| Long Term Investments Designated for Real Estate Purchase Transferred to Cash   | 3,200,000                            |                     |
| <b>Net Decrease in Cash and Cash Equivalents</b>  | <b>(771,521)</b>                     | <b>(1,728,690)</b>  |
| Cash and Cash Equivalents, Beginning of Period.   | 4,595,570                            | 4,598,993           |
| <b>Cash and Cash Equivalents, End of Period</b>   | <b>\$ 3,824,049</b>                  | <b>\$ 2,870,303</b> |
| <b>Supplemental Disclosures of Cash Flow Information:</b>   |                                      |                     |
| Cash Paid During the Period for Income Taxes  | \$ 986,415                           | \$ 876,375          |
| Non-cash Transfer of Demonstration Equipment from Fixed Assets to Inventories   | \$ 249,514                           | \$                  |
| Non-cash Transfer from Retained Earnings to Capital Stock and Additional Paid-in Capital Due to the 5 for 4 Stock Split which was characterized as a Stock Dividend | \$                                   | \$ 12,532,681       |

Edgar Filing: ASTRO MED INC /NEW/ - Form 10-Q

See Notes to Consolidated Financial Statements

-5-



**Table of Contents****ASTRO-MED, INC.****NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****August 4, 2007****(1) Basis of Presentation**

The accompanying consolidated financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, and reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair presentation of the results of the interim periods included herein. Results of operations for the interim periods presented herein are not necessarily indicative of the results that may be expected for the full year. These financial statements do not include all disclosures associated with annual financial statements and, accordingly, should be read in conjunction with footnotes contained in the Company's annual report on Form 10-K for the year ended January 31, 2007.

The accompanying consolidated condensed financial statements include the financial statements of Astro-Med, Inc. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation.

**(2) Net Income Per Share**

Net income per common share has been computed and presented pursuant to the provisions of Statement of Financial Accounting Standards (SFAS) No. 128, Earnings Per Share. Basic net income per share is computed based on the weighted average number of shares outstanding during the periods. Diluted net income per share is computed based on the weighted average number of shares and, if dilutive, common equivalent shares for stock options outstanding during the periods.

|  |                            | Three-Months Ended |           | Six-Months Ended |           |
|--|----------------------------|--------------------|-----------|------------------|-----------|
|  |                            | August 4,          | July 29,  | August 4,        | July 29,  |
|  |                            | 2007               | 2006      | 2007             | 2006      |
| Weighted Average Common Shares Outstanding | Basic                      | 6,901,265          | 6,717,790 | 6,866,104        | 6,721,193 |
|  | Effect of Dilutive Options | 676,483            | 662,584   | 707,119          | 627,726   |
| Weighted Average Common Shares Outstanding | Diluted                    | 7,577,748          | 7,380,374 | 7,573,223        | 7,348,919 |

For the three-months and six-months ended August 4, 2007, the diluted per share amounts do not reflect 150,200 and 157,300 of options outstanding, respectively. For the three months and six months ended July 29, 2006, the diluted per share amounts do not reflect 414,641 of options outstanding. These outstanding options were not included in the effect of dilutive options because the exercise price of the options was greater than the average market price of the Company's stock during the periods presented.

**(3) Revenue Recognition**

The majority of the Company's product sales are recorded at the time of shipment, when legal title has transferred and risk of loss passes to the customer, when persuasive evidence of an arrangement exists, the Company's price to the buyer is fixed or determinable and collectibility is reasonably assured in accordance with the requirements in Staff Accounting Bulletin (SAB) 104, Revenue Recognition in Financial Statements. When a sale arrangement involves training or installation, the deliverables in the arrangement are evaluated to determine whether they represent separate units of accounting in accordance with SAB 104 and EITF 00-21, Revenue Arrangements With Multiple Deliverables. This evaluation occurs at inception of the arrangement and as each item in the arrangement is delivered. The total revenue from the arrangement is allocated to each unit of accounting based on its relative fair value. Fair value for each element is established generally based on the sales price charged when the same or similar element is sold separately. Revenue is recognized when revenue recognition criteria for each unit of accounting are met. When other significant obligations remain after products are delivered, revenue is recognized only after such obligations are fulfilled. All of the Company's equipment contains embedded operating systems and data management software which is included in the selling price of the equipment. The software is deemed incidental to the system as a whole as it is not sold separately or marketed separately and its production costs are minor as compared to those of the hardware system. Returns and customer credits are infrequent and are recorded as a reduction to sales.

## Edgar Filing: ASTRO MED INC /NEW/ - Form 10-Q

Rights of return are not included in sales arrangements. Revenue associated with products that contain specific customer acceptance criteria is not recognized before the customer acceptance criteria are satisfied.

Infrequently, the Company receives requests from customers that product being purchased from the Company be held by the Company for the customers' convenience. The Company recognizes revenue for such bill and hold arrangements in accordance with the requirements of SAB No. 104 which requires, among other things, the existence of a valid business purpose for the arrangement, the transfer of ownership of the purchased product, the readiness of the product for shipment, the use of customary payment terms, no continuing performance obligation by the Company and segregation of the product from the Company's inventories.

**Table of Contents****ASTRO-MED, INC.****NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)****August 4, 2007****(4) Share-Based Compensation**

The Company has one non-qualified stock option plan under which options may be granted to officers and key employees. Options vest over four years. Options for an aggregate of 1,375,000 shares may be granted under the non-qualified plan at option prices of not less than 50% of fair market value at the date of grant. In May 2007, the Company's shareholders approved the 2007 Equity Incentive Plan (the 2007 Plan) which is designed to provide awards in the form of options, stock appreciation rights, restricted stock awards, performance awards and other stock-based awards to executives, key employees, directors and other eligible individuals. The total number of shares of stock that may be issued pursuant to awards granted under the 2007 Plan shall not exceed 1,000,000 shares. The 2007 Plan provides for an automatic annual grant of ten-year options to purchase 5,000 shares of stock to each non-employee director upon the adjournment of each shareholder meeting. Each such option is exercisable at the fair market value as of the grant date and vests immediately prior to the next succeeding annual shareholders meeting. During the second quarter of fiscal 2008, 15,000 shares were awarded to non-employee directors pursuant to the 2007 Plan.

At August 4, 2007, options covering 331,600 shares under the non-qualified plan were available for grant.

The Company has estimated the fair value of each option grant on the date of grant using the Black-Scholes option-pricing model. The volatility assumption is based on the historical weekly price data of the Company's common stock over a period equivalent to the weighted average expected life of the Company's options. Management evaluated whether there were factors during that period which were unusual and would distort the volatility figure if used to estimate future volatility and concluded that there were no such factors. In determining the expected life of the option grants, the Company has observed the actual terms of prior grants with similar characteristics, the actual vesting schedule of the grant, and assessed the expected risk tolerance of different option groups. The risk-free interest rate is based on the actual U.S. Treasury zero coupon rates for bonds matching the expected term of the option as of the option grant date.

The fair value of stock options granted during the six months ended August 4, 2007 and July 29, 2006 was estimated on the date of grant using the following assumptions:

|                          | Six-Months Ended |               |
|--------------------------|------------------|---------------|
|                          | August 4, 2007   | July 29, 2006 |
| Risk Free Interest Rate  | 4.5%             | 3.8%          |
| Expected Volatility      | 48.1%            | 52.2%         |
| Expected Life (in years) | 5.0              | 5.0           |
| Dividend Yield           | 1.9%             | 1.6%          |

Aggregated information regarding the Company's stock option plans for the six months ended August 4, 2007 is summarized below:

|                                 | Weighted Average  |                  |                     |              |
|---------------------------------|-------------------|------------------|---------------------|--------------|
|                                 | Remaining         |                  |                     |              |
|                                 | Weighted Average  | Contractual Life | Aggregate Intrinsic |              |
|                                 | Number of Options | Exercise Price   | (in Years)          | Value        |
| Outstanding at January 31, 2007 | 1,830,078         | \$ 5.36          | 4.4                 | \$ 9,259,181 |
| Granted                         | 165,200           | 11.71            |                     |              |
| Exercised                       | (127,416)         | 5.61             |                     |              |

Edgar Filing: ASTRO MED INC /NEW/ - Form 10-Q

|                               |           |         |     |    |           |
|-------------------------------|-----------|---------|-----|----|-----------|
| Expired or canceled           | (5,363)   | 7.36    |     |    |           |
| Outstanding at August 4, 2007 | 1,862,499 | 5.90    | 4.8 | \$ | 6,408,923 |
| Exercisable at August 4, 2007 | 1,481,450 | \$ 4.96 | 3.8 | \$ | 6,152,048 |

The fair value per share for options granted were \$4.81 and \$4.79 during the first and second quarters of fiscal 2008, respectively, compared to \$4.63 during the first quarter of fiscal 2007. No options were granted during the second quarter of fiscal 2007.

Share-based compensation expense was recognized as follows:

|                                     | <b>Three-Months Ended</b> |                      | <b>Six-Months Ended</b> |                      |
|-------------------------------------|---------------------------|----------------------|-------------------------|----------------------|
|                                     | <b>August 4, 2007</b>     | <b>July 29, 2006</b> | <b>August 4, 2007</b>   | <b>July 29, 2006</b> |
| Cost of Sales                       | \$ 25,304                 | \$ 18,809            | \$ 46,526               | \$ 37,618            |
| Selling, General and Administrative | 103,635                   | 63,228               | 177,907                 | 126,456              |
| Research & Development              | 25,367                    | 17,690               | 46,643                  | 35,380               |
| Reduction in pretax income          | \$ 154,306                | \$ 99,727            | \$ 271,076              | \$ 199,454           |

As of August 4, 2007 there was \$1,058,613 of unrecognized compensation expense related to unvested options.

The Company has an Employee Stock Purchase Plan allowing eligible employees to purchase shares of common stock at a 10% discount from fair value on the date of purchase. A total of 247,500 shares were initially reserved for issuance under the Plan. During the quarter ended August 4, 2007 and July 29, 2006, 747 and 542 shares were purchased under the Plan. During the six months ended August 4, 2007 and July 29, 2006, 1,456 and 1,316 shares were purchased under the Plan. Approximately 101,800 shares remain available as of August 4, 2007.

**Table of Contents****ASTRO-MED, INC.****NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)****August 4, 2007****(5) Comprehensive Income**

The Company's total comprehensive income is as follows:

|  | <b>Three-Months Ended</b> |                   | <b>Six-Months Ended</b> |                     |
|--|---------------------------|-------------------|-------------------------|---------------------|
|  | <b>August 4,</b>          | <b>July 29,</b>   | <b>August 4,</b>        | <b>July 29,</b>     |
|  | <b>2007</b>               | <b>2006</b>       | <b>2007</b>             | <b>2006</b>         |
| <b>Comprehensive Income:</b>   |                           |                   |                         |                     |
| Net Income   | \$ 885,744                | \$ 740,209        | \$ 1,407,743            | \$ 1,283,248        |
| <b>Other Comprehensive Income (Loss):</b>                            |                           |                   |                         |                     |
| Foreign currency translation adjustments, net of tax                 | 38,008                    | 10,599            | 129,920                 | 69,675              |
| Unrealized holding gain (loss) arising during the period, net of tax | (5,128)                   | 1,315             | 9,509                   | (25,694)            |
| Other Comprehensive Income   | 32,880                    | 11,914            | 139,429                 | 43,981              |
| <b>Comprehensive Income</b>  | <b>\$ 918,624</b>         | <b>\$ 752,123</b> | <b>\$ 1,547,172</b>     | <b>\$ 1,327,229</b> |

**(6) Inventories**

Inventories are stated at the lower of cost (first-in, first-out) or market and include material, labor and manufacturing overhead. The components of inventories were as follows:

|                 | <b>August 4,</b> | <b>January 31,</b> |
|-----------------|------------------|--------------------|
|                 | <b>2007</b>      | <b>2007</b>        |
| Raw Materials   | \$ 7,346,101     | \$ 6,848,636       |
| Work-In-Process | 1,969,413        | 1,486,773          |
| Finished Goods  | 3,179,982        | 3,059,354          |
|                 | \$ 12,495,496    | \$ 11,394,763      |

**(7) Income Taxes**

The Company's effective tax rates for the periods presented herein are as follows:

|             | <b>Three-Months Ended</b> | <b>Six-Months Ended</b> |
|-------------|---------------------------|-------------------------|
| Fiscal 2008 | 40.0%                     | \$ 40.0%                |
| Fiscal 2007 | 38.7%                     | 38.0%                   |

## Edgar Filing: ASTRO MED INC /NEW/ - Form 10-Q

The Company adopted FASB Interpretation 48, Accounting for Uncertainty in Income Taxes ( FIN No. 48 ), effective February 1, 2007. FIN No. 48 clarifies the accounting for uncertainty in income taxes recognized in a company's financial statements in accordance with FAS No. 109, Accounting for Income Taxes. FIN No. 48 prescribes a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination. If the tax position is deemed more-likely-than-not to be sustainable, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50 percent likelihood of being realized upon ultimate settlement.

As a result of implementing FIN No. 48, we recognized a cumulative effect adjustment of \$1,147,633 to decrease the February 1, 2007 retained earnings balance. Prior to the adoption of FIN No. 48, our policy was to classify accruals for uncertain positions as a current liability. We reclassified \$734,788 of income tax liabilities from current to non-current liabilities because a cash settlement of these liabilities is not anticipated within one year of the balance sheet date.

We have concluded all U.S. federal income tax matters for years through fiscal 2003. During the fourth quarter of fiscal 2007, the Internal Revenue Service commenced an examination of the Company's U.S. income tax returns for fiscal 2005 and fiscal 2006. We expect to have this examination completed in the current fiscal year. It is reasonably possible that the resolution of the matters raised in the examination could have a material effect on the Company's unrecognized tax benefits.

We recognize interest expense and penalties related to income tax matters in income tax expense. In addition to the uncertain tax positions noted above, as of August 4, 2007 we had accrued \$92,691 of interest and penalties.

**Table of Contents****ASTRO-MED, INC.****NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)****August 4, 2007****(8) Segment Information**

Summarized below are the Net Sales and Segment Operating Profit for each reporting segment for three-months ended August 4, 2007 and July 29, 2006:

|                            | Net Sales     |               | Segment Operating Profit |            |
|----------------------------|---------------|---------------|--------------------------|------------|
|                            | July 29,      |               | July 29,                 |            |
|                            | August 4,     | 2006          | August 4,                | 2006       |
|                            | 2007          |               | 2007                     |            |
| T&M                        | \$ 4,500,000  | \$ 3,659,000  | \$ 888,000               | \$ 765,000 |
| Quicklabel                 | 9,661,000     | 7,858,000     | 1,075,000                | 527,000    |
| GT                         | 4,533,000     | 4,750,000     | 340,000                  | 730,000    |
| Total                      | \$ 18,694,000 | \$ 16,267,000 | 2,303,000                | 2,022,000  |
| Corporate Expenses         |               |               | 1,040,000                | 1,005,000  |
| Operating Income           |               |               | 1,263,000                | 1,017,000  |
| Other Income, Net          |               |               | 213,000                  | 190,000    |
| Income Before Income Taxes |               |               | 1,476,000                | 1,207,000  |
| Income Tax Provision       |               |               | 590,000                  | 467,000    |
| Net Income                 |               |               | \$ 886,000               | \$ 740,000 |

Summarized below are the Net Sales and Segment Operating Profit for each reporting segment for the six-months ended August 4, 2007 and July 29, 2006:

|                    | Sales         |               | Segment Operating Profit |              |
|--------------------|---------------|---------------|--------------------------|--------------|
|                    | July 29,      |               | July 29,                 |              |
|                    | August 4,     | 2006          | August 4,                | 2006         |
|                    | 2007          |               | 2007                     |              |
| T&M                | \$ 7,965,000  | \$ 7,435,000  | \$ 1,300,000             | \$ 1,231,000 |
| Quicklabel         | 18,577,000    | 15,124,000    | 1,987,000                | 922,000      |
| GT                 | 8,559,000     | 9,349,000     | 575,000                  | 1,479,000    |
| Total              | \$ 35,101,000 | \$ 31,908,000 | 3,862,000                | 3,632,000    |
| Corporate Expenses |               |               | 1,978,000                | 1,902,000    |
| Operating Income   |               |               | 1,884,000                | 1,730,000    |
| Other Income, Net  |               |               | 462,000                  | 340,000      |

Edgar Filing: ASTRO MED INC /NEW/ - Form 10-Q

|                             |              |              |
|-----------------------------|--------------|--------------|
| Income Before Income Taxes. | 2,346,000    | 2,070,000    |
| Income Tax Provision        | 938,000      | 787,000      |
| Net Income                  | \$ 1,408,000 | \$ 1,283,000 |

-9-



**Table of Contents**

**ASTRO-MED, INC.**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**

**August 4, 2007**

**(9) New Accounting Pronouncements**

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities-including an amendment of SFAS 115 ( SFAS No. 159 ). The new statement allows entities to choose, at specified election dates, to measure eligible financial assets and liabilities at fair value that are not otherwise required to be measured at fair value. If a company elects the fair value option for an eligible item, changes in that item's fair value in subsequent reporting periods must be recognized in current earnings. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007. The Company is currently evaluating the potential impact of SFAS No. 159 on our financial position and results of operations.

**(10) Purchase of Real Estate**

On March 13, 2007, the Company completed the acquisition of the Rockland, Massachusetts property for the purchase price of approximately \$3,181,000 which was paid by the Company in cash at the time of the closing.

**Table of Contents**

**ASTRO-MED, INC.**

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION**

**AND RESULTS OF OPERATIONS**

**August 4, 2007**

**Business Overview**

This section should be read in conjunction with the Condensed Consolidated Financial Statements of the Company included elsewhere herein and the Company's Form 10-K for the fiscal year ended January 31, 2007.

The Company develops and manufactures systems that have the ability to acquire, process, analyze, store and present electronic data in a variety of useable forms. The Company sells its products under brand names including Astro-Med (T&M), QuickLabel Systems (QuickLabel) and Grass Technologies, formerly known as Grass Telefactor. Products sold under the Astro-Med brand acquire and record data and print the output onto charts or electronic media. Products sold under the QuickLabel Systems brand create product and packaging labels and tags in one or many colors. Products sold under the Grass Technologies brand electronically capture and record neurological data that is used to diagnose epilepsy or to study sleep disorders. The Company supplies a range of products that include hardware, software and consumables to customers who are in a variety of industries.

The Company competes worldwide in many markets including clinical and research medicine, aerospace, automotive and general manufacturing. The Company retains a competitive position in its respective markets by virtue of proprietary technology, product reputation, delivery, technical assistance and service to customers. The Company markets its products worldwide by advertising and promotion using major national and international trade journals, scientific meetings and trade shows, direct mailing campaigns, and the internet. The products are sold by direct field sales persons as well as independent dealers and representatives. In the United States, the Company has direct field sales people located in major cities from coast to coast specializing in either T&M Recorders and Data Acquisitions systems, QuickLabel Color Label printers and media systems, or Grass Technologies Neurological Instrumentation products. Additionally, the Company has direct field sales and service centers in Canada, England, France, Germany, Italy and Holland. In the remaining parts of the world, the Company utilizes approximately 80 independent dealers and representatives selling and marketing its products in 40 countries.

**Table of Contents****ASTRO-MED, INC.****MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION****AND RESULTS OF OPERATIONS****August 4, 2007****Results of Operations****Three-Months Ended August 4, 2007 vs. Three-Months Ended July 29, 2006**

The Company reports three reporting segments consistent with its sales product groups: Test & Measurement (T&M), QuickLabel Systems (QLS) and Grass-Technologies (GT). The Company evaluates segment performance based on the segment profit before corporate and financial administration expenses.

Net Sales by product group, percent change, and percent of Total Net Sales for the three months ended August 4, 2007 and July 29, 2006 were:

|            | August 4,<br>2007 | As a<br>% of<br>Net Sales | July 29,<br>2006 | As a<br>% of<br>Net Sales | % Increase<br>Over<br>Prior Year |
|------------|-------------------|---------------------------|------------------|---------------------------|----------------------------------|
| T&M        | \$ 4,500,000      | 24.1%                     | \$ 3,659,000     | 22.5%                     | 23.0%                            |
| QuickLabel | 9,661,000         | 51.7%                     | 7,858,000        | 48.3%                     | 22.9%                            |
| GT         | 4,533,000         | 24.2%                     | 4,750,000        | 29.2%                     | (4.6)%                           |
| Total      | \$ 18,694,000     | 100.0%                    | \$ 16,267,000    | 100.0%                    | 14.9%                            |

Sales in the quarter were \$18,694,000, an increase of 14.9% from prior year's second quarter sales of \$16,267,000. Sales in the Company's T&M product group were \$4,500,000, an increase of 23.0% over the prior year. Sales in the Company's QLS product group were \$9,661,000, an increase of 22.9% over the prior year. Sales in the Company's GT product group were \$4,533,000, a 4.6% decrease from the prior year. Sales through the Company's domestic channel were \$12,629,000, up 7.4% from the prior year's second quarter sales of \$11,759,000. Sales through the Company's international channel were \$6,065,000, up 34.5% from the prior year's second quarter sales of \$4,508,000. The favorable impact of the change in foreign exchange rates was approximately \$234,000 during the quarter. Had this favorable impact not occurred, sales through the Company's international channel would have been up 29.4% from the prior year.

The Company's hardware and software sales were \$9,184,000 for the quarter, up 15.3% from the prior year's sales of \$7,962,000. The increase from the prior year was driven by the T&M and QuickLabel product lines.

The Company's consumable sales were \$7,925,000 for the quarter, up 10.8% from the prior year's sales of \$7,149,000. The growth in the consumable sales was driven by QuickLabel consumable products. T&M and Grass Technologies consumable products were essentially flat with the prior year.

Sales of the Company's service and related products were \$1,585,000 for the quarter, up 37.1% from the prior year's sales of \$1,156,000. The increase was driven primarily by the sale of T&M replacement parts.

Gross profit dollars were \$7,830,560 which generated a gross profit margin of 41.9% for the quarter as compared to 43.0% for the second quarter in the prior year. The lower gross margin in the quarter is attributed to product mix and higher manufacturing costs brought on by the introduction of new products.

Operating expenses in the second quarter were \$6,568,310, compared to \$5,978,900 in the second quarter of the prior year. Selling and general administrative (SG&A) spending increased 7.9% from last year to \$5,433,462. The increase was driven by higher personnel costs, travel and advertising expenses and professional fees. During the second quarter the Company spent approximately \$60,000 in connection with

## Edgar Filing: ASTRO MED INC /NEW/ - Form 10-Q

preparations related to Sarbanes-Oxley 404 requirements. As a percent of sales, SG&A was 29.1% in the current quarter compared to 30.9% in the prior year. Research & development spending increased 20.2% from the prior year to \$1,134,848 as a result of higher personnel costs. As a percent of sales, R&D spending was 6.1% in the second quarter of the current year compared to 5.8% in the second quarter of the prior year. Operating income was \$1,262,250 in the current quarter which represented a 24.1% increase over the prior year's operating income of \$1,017,379. Operating margins were 6.7% in the current quarter compared to 6.2% in the prior year.

Other income in the current quarter was \$214,050, compared to \$190,410 in the second quarter of the prior year. The increase of \$23,640 was driven by higher investment income and miscellaneous income partially offset by lower foreign currency transaction gains.

Income tax expense was \$590,556 in the current quarter, resulting in an effective tax rate of 40.0%. This compares to an income tax expense of \$467,580, resulting in an effective tax rate of 38.7% in the prior year. The increase is the result of lower expected tax credits in the current year.

Summarized below are the Net Sales and Segment Operating Profit for each reporting segment for three-months ended August 4, 2007 and July 29, 2006:

|                            | Net Sales            |                      | Segment Operating Profit |                  |
|----------------------------|----------------------|----------------------|--------------------------|------------------|
|                            | August 4,<br>2007    | July 29,<br>2006     | August 4,<br>2007        | July 29,<br>2006 |
| T&M                        | \$ 4,500,000         | \$ 3,659,000         | \$ 888,000               | \$ 765,000       |
| QuickLabel                 | 9,661,000            | 7,858,000            | 1,075,000                | 527,000          |
| GT                         | 4,533,000            | 4,750,000            | 340,000                  | 730,000          |
| <b>Total</b>               | <b>\$ 18,694,000</b> | <b>\$ 16,267,000</b> | <b>2,303,000</b>         | <b>2,022,000</b> |
| Corporate Expenses         |                      |                      | 1,040,000                | 1,005,000        |
| Operating Income           |                      |                      | 1,263,000                | 1,017,000        |
| Other Income, Net          |                      |                      | 213,000                  | 190,000          |
| Income Before Income Taxes |                      |                      | 1,476,000                | 1,207,000        |
| Income Tax Provision       |                      |                      | 590,000                  | 467,000          |
| Net Income                 |                      |                      | \$ 886,000               | \$ 740,000       |

**Table of Contents****ASTRO-MED, INC.****MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION****AND RESULTS OF OPERATIONS****August 4, 2007****Results of Operations (continued):****Test & Measurement – T&M**

T&M's sales were \$4,500,000 for the quarter compared to \$3,659,000 for the same quarter in the prior year. The increase of \$841,000, or 23.0% in T&M sales was driven by higher Ruggedized and Dash product sales. T&M consumable sales were essentially flat and Service and Other sales increased during the quarter as a result of higher T&M replacement parts. T&M segment operating margins were 19.7% in the current quarter compared to 20.8% in the prior year. The slight decrease was driven by lower gross profit margins from product mix and higher selling and R&D costs.

**QuickLabel Systems – OLS**

QuickLabel sales were \$9,661,000 for the quarter compared to \$7,858,000 for the same quarter in the prior year. The increase of \$1,803,000, or 22.9% was driven by increases in both hardware and consumable sales. The increase in hardware sales was driven by VIVO color printers and the recent introduction of the ZEO color printers. The increase in consumable sales was driven by media products and the VIVO consumable sales. Service & Other sales were up slightly for the quarter. QuickLabel segment operating margins were 11.1% in the current quarter compared to 6.7% in the prior year. The increase from the prior year was driven by higher sales and higher gross margin dollars resulting from the increase in hardware sales.

**Grass Technologies – GT**

GT sales were \$4,533,000 for the quarter compared to \$4,750,000 for the same quarter in the prior year. The decrease of \$217,000, or 4.6% was driven almost entirely by a decrease in research products. Clinical products and consumable products were essentially flat with the prior year. Service and Other sales were up slightly during the quarter. GT segment operating profit margins were 7.5% for the quarter compared to 15.4% in the prior year. The decrease from the prior year was driven by lower sales, higher manufacturing costs and an increase in R&D spending.

**Six-Months Ended August 4, 2007 vs. Six-Months Ended July 29, 2006**

Net Sales by product group, percent change, and percent of Total Net sales for the six months ended August 4, 2007 and July 29, 2006 were:

|            | As a          |           | As a          |           |            |
|------------|---------------|-----------|---------------|-----------|------------|
|            | August 4,     | % of      | July 29,      | % of      | % Change   |
|            | 2007          | Net Sales | 2006          | Net Sales | Over       |
|            |               |           |               |           | Prior Year |
| T&M        | \$ 7,965,000  | 22.7%     | \$ 7,435,000  | 23.3%     | 7.1%       |
| QuickLabel | 18,577,000    | 52.9%     | 15,124,000    | 47.4%     | 22.8%      |
| GT         | 8,559,000     | 24.4%     | 9,349,000     | 29.3%     | (8.4)%     |
| Total      | \$ 35,101,000 | 100.0%    | \$ 31,908,000 | 100.0%    | 10.0%      |

## Edgar Filing: ASTRO MED INC /NEW/ - Form 10-Q

Sales for the first six-months of the current fiscal year were \$35,101,000, a 10.0% increase over the \$31,908,000 for the first six-months of the prior fiscal year. T&M sales were \$7,965,000, an increase of 7.1% from the prior year. QuickLabel sales were \$18,577,000, an increase of 22.8% from the prior year. GT sales were \$8,559,000, an 8.4% decrease from the prior year. Sales through our domestic channel were \$24,576,000, up 7.6% from the previous year's domestic channel sales of \$22,848,000. Sales through the Company's international channels were \$10,525,000, up 16.1% from the prior year's international channel sales of \$9,061,000. The favorable impact of the change in foreign exchange rates was approximately \$477,000 during the first six months. Had this favorable impact not occurred, sales through the Company's international channel would have been up 10.9% from the prior year.

The Company's hardware and software sales were \$16,345,000 for the six months, up 2.6% from the prior year's sales of \$15,934,000. The increase from the prior year was driven by QuickLabel hardware. T&M hardware was up only slightly and Grass Technologies hardware sales were down from the prior year.

The Company's consumable sales were \$15,832,000 for the six months, up 16.4% from the prior year's sales of \$13,599,000. The increase from the prior year was driven by QuickLabel consumable sales. GT consumable sales were up nominally while T&M consumable sales were approximately flat with the prior year.

Service and Other sales were \$2,924,000 for the six months, up 23.1% from the prior year's sales of \$2,375,000. The increase was driven by T&M replacement parts.

Gross profit dollars were \$14,676,864, which generated a gross profit margin of 41.8% for the six-months of the current year as compared to a gross profit margin of 41.6% for the first six-months of the prior year. The nominal change in gross profit margin for the six months of the current year is traceable to product mix and higher manufacturing costs.

Operating expenses for the six-months were \$12,793,203 compared to \$11,542,402 for the same period in the prior year. SG&A spending rose 10.6% to \$10,560,098. The increase in SG&A spending is attributable to the increase in field sales personnel costs, incremental advertising and travel expenses and higher professional fees. For the six months the Company has spent approximately \$76,000 in connection with preparations related to Sarbanes-Oxley 404 requirements. As a percent of sales, SG&A was 30.1% in the current year as compared to 29.9% in the prior year. R&D spending increased 11.8% from the prior year to \$2,233,105 as a result of higher personnel costs. As a percent of sales, R&D spending was 6.4% in the current year approximately flat with 6.3% in the prior year. Operating income was \$1,883,661 in the current year, representing an 8.9% increase over the prior year's operating income of \$1,729,597. Operating margins were 5.4% in the current year, consistent with the prior year's operating margin of 5.4%.

Other income for the current year was \$462,671 compared to \$340,157 for the prior year. The increase of \$122,514 was driven by higher investment income, higher foreign currency transaction gains and an increase in miscellaneous income.

**Table of Contents****ASTRO-MED, INC.****MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION****AND RESULTS OF OPERATIONS****August 4, 2007****Results of Operations (continued):****Six-Months Ended August 4, 2007 vs. Six-Months Ended July 29, 2006**

Income tax expense of \$938,589 was recorded for the current year resulting in an effective tax rate of 40.0%. This compares to \$786,506 in the prior year resulting in an effective tax rate of 38.0%. The increase is the result of lower expected tax credits in the current year.

Summarized below are the Net sales and Segment Operating Profit for each reporting segment for the six-months ended August 4, 2007 and July 29, 2006:

|                             | Net Sales     |               | Segment Operating Profit |              |
|-----------------------------|---------------|---------------|--------------------------|--------------|
|                             | July 29,      |               | July 29,                 |              |
|                             | August 4,     | 2006          | August 4,                | 2006         |
|                             | 2007          |               | 2007                     |              |
| T&M                         | \$ 7,965,000  | \$ 7,435,000  | \$ 1,300,000             | \$ 1,231,000 |
| QuickLabel                  | 18,577,000    | 15,124,000    | 1,987,000                | 922,000      |
| GT                          | 8,559,000     | 9,349,000     | 575,000                  | 1,479,000    |
| Total                       | \$ 35,101,000 | \$ 31,908,000 | 3,862,000                | 3,632,000    |
| Corporate Expenses          |               |               | 1,978,000                | 1,902,000    |
| Operating Income            |               |               | 1,884,000                | 1,730,000    |
| Other Income, Net           |               |               | 462,000                  | 340,000      |
| Income Before Income Taxes. |               |               | 2,346,000                | 2,070,000    |
| Income Tax Provision        |               |               | 938,000                  | 787,000      |
| Net Income                  |               |               | \$ 1,408,000             | \$ 1,283,000 |

**Table of Contents**

**ASTRO-MED, INC.**

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION**

**AND RESULTS OF OPERATIONS**

**August 4, 2007**

**Results of Operations (continued):**

**Six-Months Ended August 4, 2007 vs. Six-Months Ended July 29, 2006 (Continued)**

**Test & Measurement - T&M**

T&M's sales were \$7,965,000 for the six months compared to \$7,435,000 for the same period in the prior year. The increase of 7.1% in T&M sales was driven by higher Ruggedized and Dash product hardware sales. T&M consumable sales were approximately flat with the prior year with Service and Other sales being up due to higher replacement parts. T&M segment operating margins were 16.3% in the current year compared to 16.5% in the prior year. The nominal decrease in operating margins was driven by lower gross profit margins and higher R&D costs.

**QuickLabel Systems - OLS**

QuickLabel sales were \$18,577,000 for the six months compared to \$15,124,000 for the same period in the prior year. The increment of \$3,453,000, or 22.8% was traceable to hardware and consumable sales. The hardware increase was due to sales of VIVO color printers and the recently introduced ZEO color printers. The growth in consumable sales was shared by media products and VIVO consumable sales. Service & Other sales were also up for the current year. QuickLabel segment operating margins were 10.7% in the current year compared to 6.1% in the prior year. The increase in operating margins from the prior year was driven by higher sales and higher gross margin dollars resulting from the increase in hardware sales.

**Grass Technologies - GT**

GT sales were \$8,559,000 for the six months compared to \$9,349,000 for the same period in the prior year. The decrease of \$790,000, or 8.4% was caused by lower research product sales and lower sleep system sales in the first quarter of the current fiscal year. GT consumable sales were up from the prior year. Service and Other sales were also up from the prior year. GT segment operating profit margins were 6.7% for the current year compared to 15.8% in the prior year. The lower operating profit margin was driven by lower sales, higher manufacturing costs and an increase in development spending.

**Financial Condition and Liquidity:**

The Company expects to finance its future working capital needs, capital expenditures and acquisition requirements through internal funds. To the extent the Company's capital and liquidity requirements are not satisfied internally, the Company may utilize a \$3.5 million unsecured bank line of credit, all of which is currently available. Borrowings under this line of credit bear interest at the bank's prime rate. The expiration date of this line of credit is July 31, 2009.

The Company's Statements of Cash Flows for the six-months ended August 4, 2007 and July 29, 2006 are included on page 5. Net cash flows used by Operating Activities were \$670,347 in the current year compared to Net Cash Flows provided by Operating Activities of \$1,429,923 in the prior year. The use of cash in the current year is the result of higher Accounts Receivable and Inventory balances and lower liabilities including the reduction in Accounts Payable and Accrued Expenses since year end. Accounts receivable increased to \$12,832,157 at the end of the second quarter compared to \$12,112,676 at year-end. The accounts receivable collection cycle remained at 62 net days sales outstanding at



## Edgar Filing: ASTRO MED INC /NEW/ - Form 10-Q

the end of the quarter as compared to 62 net days outstanding at year-end. Inventory increased to \$12,495,496 at the end of the second quarter compared to \$11,394,763 at year-end. Inventory turns slowed to 3.5 turns at the end of the quarter as compared to 3.6 turns at year-end.

Cash and cash equivalents and investments at the end of the second quarter totaled \$15,904,727 compared to \$20,129,635 at year-end. The lower cash and investments position can be attributed to cash used by operations of \$670,347, capital expenditures of \$3,729,467 including the purchase of the Rockland property for approximately \$3,181,000 and the payment of dividends of \$688,836. These uses of cash were partially offset by proceeds from the exercise of stock options of \$729,381.

Backlog was \$6,842,000 at the end of the second quarter compared to \$5,959,000 at year-end.

## **Table of Contents**

### **Critical Accounting Policies, Commitments and Certain Other Matters:**

In the Company's Form 10-K for the year ended January 31, 2007, the Company's most critical accounting policies and estimates upon which our financial status depends were identified as those relating to revenue recognition, warranty claims, bad debts, customer returns, inventories and long-lived assets. We considered the disclosure requirements of Financial Release (FR) 60 (FR-60) regarding critical accounting policies and FR-61 regarding liquidity and capital resources, certain trading activities and related party/certain other disclosures, and concluded that nothing materially changed during the quarter that would warrant further disclosure under these releases.

### **Safe Harbor Statement**

This document contains forward-looking statements based on current expectations that involve a number of risks and uncertainties. Factors which could cause actual results to differ materially from those anticipated are described in Item 1A of the Company's Form 10-K for the fiscal year ended January 31, 2007.

### **Item 3. Quantitative and Qualitative Disclosure about Market Risk**

The Company's exposure to market risk has not changed materially from its exposure at January 31, 2007 as set forth in Item 7A in its Form 10-K for the fiscal year ended January 31, 2007.

### **Item 4. Controls and Procedures**

As required by Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the Exchange Act), the Company conducted an evaluation under the supervision and with the participation of the Company's management, including the Chairman of the Board (serving as the principal executive officer) and the Chief Financial Officer, of the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chairman of the Board and the Chief Financial Officer concluded that the disclosure controls and procedures are effective in ensuring that all information required to be disclosed in reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms. There was no significant change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

## **Part II. Other Information**

### **Item 1. Legal Proceedings**

There are no pending or threatened legal proceedings against the Company believed to be material to the financial position or results of operations of the Company.

### **Item 1A. Risk Factors**

*Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business and stock price.*

We are in the process of documenting and testing our internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act, which requires annual management assessments of the effectiveness of our internal controls over financial reporting and a report by our independent auditors, beginning in fiscal 2009, regarding our assessments. During the course of our testing we may identify deficiencies which we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act and regulations thereunder for compliance with the requirements of Section 404. In addition, if we fail to maintain the adequacy of our internal controls, as such standards are modified, supplemented or amended from time to time; we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act. Failure to achieve and maintain an effective internal control environment could have a material adverse effect on our stock price.

Edgar Filing: ASTRO MED INC /NEW/ - Form 10-Q

There are no other changes to the risk factors disclosed in Item 1A to the Company's Form 10-K for the fiscal year ended January 31, 2007.

-16-

**Table of Contents**

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

On August 16, 2004, the Company announced that its Board of Directors had approved the repurchase of 600,000 shares of common stock. This is an ongoing authorization without any expiration date. The Company made no purchases of its common stock pursuant to this authority during the second quarter of fiscal 2008. Currently, the Company can repurchase an additional 447,589 shares under the current program.

**Item 4. Submission of Matters to a Vote of Stockholders**

The Company's Annual Meeting of Shareholders was held May 15, 2007.

In an uncontested election, nominees for directors were elected by the following votes:

| Name of Nominee for Director | Votes     | Votes    |
|------------------------------|-----------|----------|
|                              | For       | Withheld |
| Albert W. Ondis              | 6,237,773 | 352,101  |
| Everett V. Pizzuti           | 6,233,500 | 356,374  |
| Jacques V. Hopkins           | 6,227,465 | 362,409  |
| Hermann Viets                | 6,229,452 | 360,422  |
| Graeme MacLetchie            | 6,241,753 | 348,121  |

The shareholders approved and adopted the 2007 Equity Incentive Plan by the following vote:

| For       | Against   | Abstain |
|-----------|-----------|---------|
| 3,740,213 | 1,143,368 | 12,811  |

**Table of Contents**

**Item 6. Exhibits**

(a) Exhibits:

The following exhibits are filed as part of this report on Form 10-Q:

- 10.7 2007 Equity Incentive Plan (Incorporated by reference to Appendix A to the Company's Definitive Proxy Statement on Schedule 14A filed on April 25, 2007)
  - 31.1 Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)
  - 31.2 Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)
  - 32.1 Certification of Chief Executive Officer Pursuant to Rule 13a-14(b) and 18 U.S.C. 1350
  - 32.2 Certification of Chief Financial Officer Pursuant to Rule 13a-14(b) and 18 U.S.C. 1350
- SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ASTRO-MED, INC.  
(Registrant)

Date: September 7, 2007

By /s/ A. W. Ondis  
A. W. Ondis,  
Chairman and Chief Executive Officer  
(Principal Executive Officer)

Date: September 7, 2007

By /s/ Joseph P. O'Connell  
Joseph P. O'Connell,  
Senior Vice President, Treasurer and Chief Financial Officer  
(Principal Financial Officer)